Dr. Oxnard on the Role of Osimertinib in the TATTON Trial for Lung Cancer
Geoffrey R. Oxnard, MD, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the role of osimertinib (Tagrisso) in the TATTON trial for patients with lung cancer.
Geoffrey R. Oxnard, MD, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the role of osimertinib (Tagrisso) in the TATTON trial for patients with lung cancer.
The TATTON trial investigated osimertinib plus different combination therapies of durvalumab (Imfinzi), selumetinib, and savolitinib, states Oxnard.
Osimertinib with durvalumab was shown to be toxic, while osimertinib with selumetinib was found to be tolerable. Osimertinib and savolitinib is the combination that is moving forward to phase II development, explains Oxnard.
